Neuropsychopharmacology of auditory hallucinations: insights from pharmacological functional MRI and perspectives for future research

References

• David AS. Auditory hallucinations: phenomenology, neuropsychology and neuroimaging update. Acta Psychiatr. Scand. Suppl. 395, 95–104 (1999).
   PubMedGoogle Scholar
• Hugdahl K, Løberg EM, Nygård M. Left temporal lobe structural and functional abnormality underlying auditory hallucinations in schizophrenia. Front. Neurosci. 3(1), 34–45 (2009).
   PubMed Web of Science ®Google Scholar
• Wing JK, Cooper JE, Sartorius N. In: Measurement and Classification of Psychiatric Symptoms. Cambridge University Press, UK (1974).
   Google Scholar
• Johns LC, van Os J. The continuity of psychotic experiences in the general population. Clin. Psychol. Rev. 21(8), 1125–1141 (2001).
   PubMed Web of Science ®Google Scholar
• Sommer IE, Daalman K, Rietkerk T et al. Healthy individuals with auditory verbal hallucinations; who are they? Psychiatric assessments of a selected sample of 103 subjects. Schizophr. Bull. 36(3), 633–641 (2010).
   PubMed Web of Science ®Google Scholar
• Daalman K, Boks MP, Diederen KM et al. The same or different? A phenomenological comparison of auditory verbal hallucinations in healthy and psychotic individuals. J. Clin. Psychiatry 72(3), 320–325 (2011).
   PubMed Web of Science ®Google Scholar
• Kompus K, Westerhausen R, Hugdahl K. The ‘paradoxical’ engagement of the primary auditory cortex in patients with auditory verbal hallucinations: a meta-analysis of functional neuroimaging studies. Neuropsychologia 49(12), 3361–3369 (2011).
   PubMed Web of Science ®Google Scholar
• Aleman A, Vercammen A. Functional neuroimaging in hallucinations. In: Hallucinations – Research and Practice. Blom JD, Sommer IEC (Eds). Springer Verlag, NY, USA (2012).
   Google Scholar
• Jardri R, Pouchet A, Pins D, Thomas P. Cortical activations during auditory verbal hallucinations in schizophrenia: a coordinate-based meta-analysis. Am. J. Psychiatry 168(1), 73–81 (2011).
   PubMed Web of Science ®Google Scholar
• Plaze M, Bartrés-Faz D, Martinot JL et al. Left superior temporal gyrus activation during sentence perception negatively correlates with auditory hallucination severity in schizophrenia patients. Schizophr. Res. 87(1–3), 109–115 (2006).
   PubMed Web of Science ®Google Scholar
• McGuire P, Howes OD, Stone J, Fusar-Poli P. Functional neuroimaging in schizophrenia: diagnosis and drug discovery. Trends Pharmacol. Sci. 29(2), 91–98 (2008).
   PubMed Web of Science ®Google Scholar
• Smieskova R, Fusar-Poli P, Allen P et al. The effects of antipsychotics on the brain: what have we learnt from structural imaging of schizophrenia? – a systematic review. Curr. Pharm. Des. 15(22), 2535–2549 (2009).
   PubMed Web of Science ®Google Scholar
• Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch. Gen. Psychiatry 68(2), 128–137 (2011).
   PubMed Web of Science ®Google Scholar
• Honey G, Bullmore E. Human pharmacological MRI. Trends Pharmacol. Sci. 25(7), 366–374 (2004).
   PubMed Web of Science ®Google Scholar
• Leslie RA, James MF. Pharmacological magnetic resonance imaging: a new application for functional MRI. Trends Pharmacol. Sci. 21(8), 314–318 (2000).
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, Borgwardt S, Bechdolf A et al. The psychosis high risk state: a comprehensive state of the art review. Arch. Gen. Psychiatry 19, 1–4 (2012).
   Google Scholar
• Fusar-Poli P, Bonoldi I, Yung AR et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch. Gen. Psychiatry 69(3), 220–229 (2012).
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, Bechdolf A, Taylor M et al. At risk for schizophrenic or affective psychosis? A meta-analysis of ICD/DSM diagnostic outcomes in individuals at high clinical risk Schizophr. Bull. doi:10.1093/schbul/sbs060 (2012) (Epub ahead of print).
   Google Scholar
• Fusar-Poli P, Deste G, Smieskova R et al. Cognitive functioning in prodromal psychosis: a meta-analysis. Arch. Gen. Psychiatry 69(6), 562–571 (2012).
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, Radua J, McGuire P, Borgwardt S. Neuroanatomical maps of psychosis onset: voxel-wise meta-analysis of antipsychotic-naive VBM studies. Schizophr. Bull. 38(6), 1297–1307 (2012).
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, Borgwardt S, Crescini A et al. Neuroanatomy of vulnerability to psychosis: a voxel-based meta-analysis. Neurosci. Biobehav. Rev. 35(5), 1175–1185 (2011).
   PubMed Web of Science ®Google Scholar
• Smieskova R, Fusar-Poli P, Allen P et al. Neuroimaging predictors of transition to psychosis – a systematic review and meta-analysis. Neurosci. Biobehav. Rev. 34(8), 1207–1222 (2010).
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, Perez J, Broome M et al. Neurofunctional correlates of vulnerability to psychosis: a systematic review and meta-analysis. Neurosci. Biobehav. Rev. 31(4), 465–484 (2007).
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, Howes OD, Allen P et al. Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study. Arch. Gen. Psychiatry 67(7), 683–691 (2010).
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, Howes OD, Allen P et al. Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol. Psychiatry 16(1), 67–75 (2011).
   PubMed Web of Science ®Google Scholar
• Crossley NA, Mechelli A, Fusar-Poli P et al. Superior temporal lobe dysfunction and frontotemporal dysconnectivity in subjects at risk of psychosis and in first-episode psychosis. Hum. Brain Mapp. 30(12), 4129–4137 (2009).
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, Meyer-Lindenberg A. Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [18F]/[11C] DOPA PET studies. Schizophr. Bull. doi:10.1093/schbul/sbr180 (2012) (Epub ahed of print).
   Google Scholar
• Fusar-Poli P, Stone JM, Broome MR et al. Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosis. Arch. Gen. Psychiatry 68(9), 881–890 (2011).
   PubMed Web of Science ®Google Scholar
• Howes OD, Montgomery AJ, Asselin MC et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch. Gen. Psychiatry 66(1), 13–20 (2009).
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, Howes OD, McGuire P. Pseudohallucinations versus true hallucinations in prodromal psychosis: does it really matter? J. Clin. Psychiatry 70(7), 1056–1057 (2009).
   PubMed Web of Science ®Google Scholar
• Strauss JS. Hallucinations and delusions as points on continua function. Rating scale evidence. Arch. Gen. Psychiatry 21(5), 581–586 (1969).
   PubMed Web of Science ®Google Scholar
• van Os J, Hanssen M, Bijl RV, Vollebergh W. Prevalence of psychotic disorder and community level of psychotic symptoms: an urban-rural comparison. Arch. Gen. Psychiatry 58(7), 663–668 (2001).
   PubMed Web of Science ®Google Scholar
• Tien AY. Distributions of hallucinations in the population. Soc. Psychiatry Psychiatr. Epidemiol. 26(6), 287–292 (1991).
   PubMed Web of Science ®Google Scholar
• Delay J, Deniker P, Harl JM. Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP). Ann. Med. Psychol. (Paris) 110, 112–117 (1952).
   PubMedGoogle Scholar
• López-Muñoz F, Alamo C, Cuenca E, Shen WW, Clervoy P, Rubio G. History of the discovery and clinical introduction of chlorpromazine. Ann. Clin. Psychiatry 17(3), 113–135 (2005).
   PubMedGoogle Scholar
• Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol. Psychiatry 14(4), 429–447 (2009).
   PubMed Web of Science ®Google Scholar
• van Os J, Kapur S. Schizophrenia. Lancet 374(9690), 635–645 (2009).
   PubMed Web of Science ®Google Scholar
• Tandon R, Belmaker RH, Gattaz WF. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr. Res. 100(1–3), 20–38 (2008).
   PubMed Web of Science ®Google Scholar
• Shen WW. A history of antipsychotic drug development. Compr. Psychiatry 40(6), 407–414 (1999).
   PubMed Web of Science ®Google Scholar
• Carlsson A. Does dopamine have a role in schizophrenia? Biol. Psychiatr. (1978).
   PubMedGoogle Scholar
• Fusar-Poli P, Meyer-Lindenberg A. Striatal presynaptic dopamine in schizophrenia, part I: meta-analysis of Dopamine Active Transporter (DAT) density. Schizophr. Bull. doi:10.1093/schbul/sbr111 (2012) (Epub ahead of print).
   Google Scholar
• Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III – the final common pathway. Schizophr. Bull. 35(3), 549–562 (2009).
   PubMed Web of Science ®Google Scholar
• Howes OD, Bose SK, Turkheimer F et al. Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. Am. J. Psychiatry 168(12), 1311–1317 (2011).
   PubMed Web of Science ®Google Scholar
• Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res. Brain Res. Rev. 28(3), 309–369 (1998).
   PubMed Web of Science ®Google Scholar
• Heinz A, Schlagenhauf F. Dopaminergic dysfunction in schizophrenia: salience attribution revisited. Schizophr. Bull. 36(3), 472–485 (2010).
   PubMed Web of Science ®Google Scholar
• Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog. Neuropsychopharmacol. Biol. Psychiatry 27(7), 1081–1090 (2003).
   PubMed Web of Science ®Google Scholar
• Kapur S, Mizrahi R, Li M. From dopamine to salience to psychosis – linking biology, pharmacology and phenomenology of psychosis. Schizophr. Res. 79(1), 59–68 (2005).
   PubMed Web of Science ®Google Scholar
• Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. 3(4), 353–359 (2004).
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr. Opin. Pharmacol. 11(1), 59–67 (2011).
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 251(1), 238–246 (1989).
   PubMed Web of Science ®Google Scholar
• Lewis DA, Sweet RA. Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies. J. Clin. Invest. 119(4), 706–716 (2009).
   PubMed Web of Science ®Google Scholar
• van Wageningen H, Jørgensen HA, Specht K, Hugdahl K. A 1H-MR spectroscopy study of changes in glutamate and glutamine (Glx) concentrations in frontal spectra after administration of memantine. Cereb. Cortex 20(4), 798–803 (2010).
   PubMed Web of Science ®Google Scholar
• Lewis DA. The chandelier neuron in schizophrenia. Dev. Neurobiol. 71(1), 118–127 (2011).
   PubMed Web of Science ®Google Scholar
• Akil M, Pierri JN, Whitehead RE et al. Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am. J. Psychiatry 156(10), 1580–1589 (1999).
   PubMed Web of Science ®Google Scholar
• Kantrowitz JT, Javitt DC. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res. Bull. 83(3–4), 108–121 (2010).
   PubMed Web of Science ®Google Scholar
• Tzschentke TM. Glutamatergic mechanisms in different disease states: overview and therapeutical implications – an introduction. Amino Acids 23(1–3), 147–152 (2002).
   PubMed Web of Science ®Google Scholar
• Kalia LV, Kalia SK, Salter MW. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol. 7(8), 742–755 (2008).
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol. Psychiatry 17(12), 1206–1227 (2012).
   PubMed Web of Science ®Google Scholar
• Falkenberg LE, Westerhausen R, Specht K, Hugdahl K. Resting-state glutamate level in the anterior cingulate predicts blood-oxygen level-dependent response to cognitive control. Proc. Natl Acad. Sci. USA 109(13), 5069–5073 (2012).
   PubMed Web of Science ®Google Scholar
• Hugdahl K, Beyer M, Brix M, Ersland L. Autism spectrum disorder, functional MRI and MR spectroscopy: possibilities and challenges. Microb. Ecol. Health. Dis. (2012) (In Press).
   PubMedGoogle Scholar
• Yin DM, Chen YJ, Sathyamurthy A, Xiong WC, Mei L. Synaptic dysfunction in schizophrenia. Adv. Exp. Med. Biol. 970, 493–516 (2012).
   PubMed Web of Science ®Google Scholar
• Adler LE, Hoffer LD, Wiser A, Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am. J. Psychiatry 150(12), 1856–1861 (1993).
   PubMed Web of Science ®Google Scholar
• Adler LE, Hoffer LJ, Griffith J, Waldo MC, Freedman R. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol. Psychiatry 32(7), 607–616 (1992).
   PubMed Web of Science ®Google Scholar
• Pinto T, Lanctôt KL, Herrmann N. Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer’s type. Ageing Res. Rev. 10(4), 404–412 (2011).
   PubMed Web of Science ®Google Scholar
• Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson’s disease: a review. Drugs Aging 25(8), 665–682 (2008).
   PubMed Web of Science ®Google Scholar
• Moncrieff J, Leo J. A systematic review of the effects of antipsychotic drugs on brain volume. Psychol. Med. 40(9), 1409–1422 (2010).
   PubMed Web of Science ®Google Scholar
• Hakak Y, Walker JR, Li C et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc. Natl Acad. Sci. USA 98(8), 4746–4751 (2001).
   PubMed Web of Science ®Google Scholar
• Höistad M, Segal D, Takahashi N, Sakurai T, Buxbaum JD, Hof PR. Linking white and grey matter in schizophrenia: oligodendrocyte and neuron pathology in the prefrontal cortex. Front. Neuroanat. 3, 9 (2009).
   PubMedGoogle Scholar
• Takahashi N, Sakurai T, Davis KL, Buxbaum JD. Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia. Prog. Neurobiol. 93(1), 13–24 (2011).
   PubMed Web of Science ®Google Scholar
• Garver DL, Holcomb JA, Christensen JD. Compromised myelin integrity during psychosis with repair during remission in drug-responding schizophrenia. Int. J. Neuropsychopharmacol. 11(1), 49–61 (2008).
   PubMed Web of Science ®Google Scholar
• Kimoto S, Okuda A, Toritsuka M et al. Olanzapine stimulates proliferation but inhibits differentiation in rat oligodendrocyte precursor cell cultures. Prog. Neuropsychopharmacol. Biol. Psychiatry 35(8), 1950–1956 (2011).
   PubMed Web of Science ®Google Scholar
• Xiao L, Xu H, Zhang Y et al. Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes. Mol. Psychiatry 13(7), 697–708 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xu H, Jiang W et al. Quetiapine alleviates the cuprizone-induced white matter pathology in the brain of C57BL/6 mouse. Schizophr. Res. 106(2–3), 182–191 (2008).
   PubMed Web of Science ®Google Scholar
• Whitford TJ, Ford JM, Mathalon DH, Kubicki M, Shenton ME. Schizophrenia, myelination, and delayed corollary discharges: a hypothesis. Schizophr. Bull. 38(3), 486–494 (2012).
   PubMed Web of Science ®Google Scholar
• Huettel SA, Song AW, Mccarthy G. Functional Magnetic Resonance Imaging. Sinauer Associates Sunderland, MA, USA (2004).
   Google Scholar
• Iannetti GD, Wise RG. BOLD functional MRI in disease and pharmacological studies: room for improvement? Magn. Reson. Imaging 25(6), 978–988 (2007).
   PubMed Web of Science ®Google Scholar
• Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 8(3), 457–472 (2005).
   PubMed Web of Science ®Google Scholar
• Johnsen E, Jørgensen HA, Kroken RA, Løberg EM. Neurocognitive effectiveness of quetiapine, olanzapine, risperidone, and ziprasidone: a pragmatic, randomized trial. Eur. Psychiatry doi:10.1016/j.eurpsy.2011.10.003 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Riedel M, Schennach-Wolff R, Musil R et al. Neurocognition and its influencing factors in the treatment of schizophrenia-effects of aripiprazole, olanzapine, quetiapine and risperidone. Hum. Psychopharmacol. 25(2), 116–125 (2010).
   PubMed Web of Science ®Google Scholar
• Davidson M, Galderisi S, Weiser M et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am. J. Psychiatry 166(6), 675–682 (2009).
   PubMed Web of Science ®Google Scholar
• Keefe RS, Bilder RM, Davis SM et al.; CATIE Investigators; Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 64(6), 633–647 (2007).
   PubMed Web of Science ®Google Scholar
• Meltzer HY. Update on typical and atypical antipsychotic drugs. Annu. Rev. Med. (2012).
   PubMedGoogle Scholar
• Brassen S, Tost H, Hoehn F, Weber-Fahr W, Klein S, Braus DF. Haloperidol challenge in healthy male humans: a functional magnetic resonance imaging study. Neurosci. Lett. 340(3), 193–196 (2003).
   PubMed Web of Science ®Google Scholar
• Tost H, Meyer-Lindenberg A, Klein S et al. D2 antidopaminergic modulation of frontal lobe function in healthy human subjects. Biol. Psychiatry 60(11), 1196–1205 (2006).
   PubMed Web of Science ®Google Scholar
• Radua J, Borgwardt S, Crescini A et al. Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and the effects of antipsychotic medication. Neurosci. Biobehav. Rev. 36(10), 2325–2333 (2012).
   PubMed Web of Science ®Google Scholar
• Röder CH, Hoogendam JM, van der Veen FM. FMRI, antipsychotics and schizophrenia. Influence of different antipsychotics on BOLD-signal. Curr. Pharm. Des. 16(18), 2012–2025 (2010).
   PubMed Web of Science ®Google Scholar
• Honey GD, Bullmore ET, Soni W, Varatheesan M, Williams SC, Sharma T. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc. Natl Acad. Sci. USA 96(23), 13432–13437 (1999).
   PubMed Web of Science ®Google Scholar
• Stephan KE, Magnotta VA, White T et al. Effects of olanzapine on cerebellar functional connectivity in schizophrenia measured by fMRI during a simple motor task. Psychol. Med. 31(6), 1065–1078 (2001).
   PubMed Web of Science ®Google Scholar
• Lund A, Kroken R, Thomsen T et al. ‘Normalization’ of brain activation in schizophrenia. An fMRI study. Schizophr. Res. 58(2–3), 333–335 (2002).
   PubMed Web of Science ®Google Scholar
• Braus DF, Ende G, Weber-Fahr W et al. Antipsychotic drug effects on motor activation measured by functional magnetic resonance imaging in schizophrenic patients. Schizophr. Res. 39(1), 19–29 (1999).
   PubMed Web of Science ®Google Scholar
• Maiza O, Mazoyer B, Hervé PY et al. Impact of cognitive performance on the reproducibility of fMRI activation in schizophrenia. J. Psychiatry Neurosci. 35(6), 378–389 (2010).
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, Broome MR, Matthiasson P, Williams SCR, Brammer M, Mcguire PK. Effects of acute antipsychotic treatment on brain activation in first episode psychosis: an fMRI study. Eur. Neuropsychopharmacol. 17(6–7), 492–500 (2007).
   PubMed Web of Science ®Google Scholar
• Ettinger U, Williams SC, Fannon D et al. Functional magnetic resonance imaging of a parametric working memory task in schizophrenia: relationship with performance and effects of antipsychotic treatment. Psychopharmacology (Berl.) 216(1), 17–27 (2011).
   PubMed Web of Science ®Google Scholar
• Liemburg EJ, Knegtering H, Klein HC, Kortekaas R, Aleman A. Antipsychotic medication and prefrontal cortex activation: a review of neuroimaging findings. Eur. Neuropsychopharmacol. 22(6), 387–400 (2012).
   PubMed Web of Science ®Google Scholar
• Eickhoff SB, Laird AR, Grefkes C, Wang LE, Zilles K, Fox PT. Coordinate-based activation likelihood estimation meta-analysis of neuroimaging data: a random-effects approach based on empirical estimates of spatial uncertainty. Hum. Brain Mapp. 30(9), 2907–2926 (2009).
   PubMed Web of Science ®Google Scholar
• Kühn S, Gallinat J. Quantitative meta-analysis on state and trait aspects of auditory verbal hallucinations in schizophrenia. Schizoph. Bull. (2011).
   Google Scholar
• Seal ML, Aleman A, McGuire PK. Compelling imagery, unanticipated speech and deceptive memory: neurocognitive models of auditory verbal hallucinations in schizophrenia. Cogn. Neuropsychiatry 9(1–2), 43–72 (2004).
   PubMedGoogle Scholar
• Schneider SD, Jelinek L, Lincoln TM, Moritz S. What happened to the voices? A fine-grained analysis of how hallucinations and delusions change under psychiatric treatment. Psychiatry Res. 188(1), 13–17 (2011).
   PubMed Web of Science ®Google Scholar
• Vercammen A, Knegtering H, Bruggeman R, Aleman A. Subjective loudness and reality of auditory verbal hallucinations and activation of the inner speech processing network. Schizophr. Bull. 37(5), 1009–1016 (2011).
   PubMed Web of Science ®Google Scholar
• Dierks T, Linden DE, Jandl M et al. Activation of Heschl’s gyrus during auditory hallucinations. Neuron 22(3), 615–621 (1999).
   PubMed Web of Science ®Google Scholar
• Shergill SS, Brammer MJ, Williams SC, Murray RM, McGuire PK. Mapping auditory hallucinations in schizophrenia using functional magnetic resonance imaging. Arch. Gen. Psychiatry 57(11), 1033–1038 (2000).
   PubMed Web of Science ®Google Scholar
• Sommer IE, Diederen KM, Blom JD et al. Auditory verbal hallucinations predominantly activate the right inferior frontal area. Brain 131(Pt 12), 3169–3177 (2008).
   PubMed Web of Science ®Google Scholar
• Linden DE, Thornton K, Kuswanto CN, Johnston SJ, van de Ven V, Jackson MC. The brain’s voices: comparing nonclinical auditory hallucinations and imagery. Cereb. Cortex 21(2), 330–337 (2011).
   PubMed Web of Science ®Google Scholar
• Barkus E, Stirling J, Hopkins R, McKie S, Lewis S. Cognitive and neural processes in non-clinical auditory hallucinations. Br. J. Psychiatry. Suppl. 51, s76–s81 (2007).
   Google Scholar
• Diederen KM, Daalman K, de Weijer AD et al. Auditory hallucinations elicit similar brain activation in psychotic and nonpsychotic individuals. Schizophr. Bull. 38(5), 1074–1082 (2012).
   PubMed Web of Science ®Google Scholar
• Howes OD, Shotbolt P, Bloomfield M et al. dopaminergic function in the psychosis spectrum: an [18F]-DOPA imaging study in healthy individuals with auditory hallucinations. Schizophr. Bull. (2012).
   Google Scholar
• Northoff G, Qin P. How can the brain’s resting state activity generate hallucinations? A ‘resting state hypothesis’ of auditory verbal hallucinations. Schizophr. Res. 127(1–3), 202–214 (2011).
   PubMed Web of Science ®Google Scholar
• Nygård M, Eichele T, Løberg EM et al. Patients with schizophrenia fail to up-regulate task-positive and down-regulate task-negative brain networks: an fMRI study using an ICA analysis approach. Front. Hum. Neurosci. 6, 149 (2012).
   PubMedGoogle Scholar
• Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. A default mode of brain function. Proc. Natl Acad. Sci. USA 98(2), 676–682 (2001).
   PubMed Web of Science ®Google Scholar
• Hunter MD, Eickhoff SB, Miller TW, Farrow TF, Wilkinson ID, Woodruff PW. Neural activity in speech-sensitive auditory cortex during silence. Proc. Natl Acad. Sci. USA 103(1), 189–194 (2006).
   PubMed Web of Science ®Google Scholar
• de Weijer AD, Neggers SF, Diederen KM et al. Aberrations in the arcuate fasciculus are associated with auditory verbal hallucinations in psychotic and in non-psychotic individuals. Hum. Brain Mapp. doi:10.1002/hbm.21463 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Hugdahl K, Løberg EM, Falkenberg LE et al. Auditory verbal hallucinations in schizophrenia as aberrant lateralized speech perception: evidence from dichotic listening. Schizophr. Res. 140(1-3), 59–64 (2012).
   PubMed Web of Science ®Google Scholar
• Sommer IE, Slotema CW, Daskalakis ZJ, Derks EM, Blom JD, van der Gaag M. The treatment of hallucinations in schizophrenia spectrum disorders. Schizophr. Bull. 38(4), 704–714 (2012).
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 13(2), 261–276 (1987).
   PubMed Web of Science ®Google Scholar
• Biedermann F, Fleischhacker WW. Emerging drugs for schizophrenia. Expert Opin. Emerg. Drugs 16(2), 271–282 (2011).
   PubMed Web of Science ®Google Scholar
• Fornito A, Bullmore ET. Connectomic intermediate phenotypes for psychiatric disorders. Front. Psychiatry 3, 32 (2012).
   PubMedGoogle Scholar
• Pratt J, Winchester C, Dawson N, Morris B. Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap. Nat. Rev. Drug Discov. 11(7), 560–579 (2012).
   PubMed Web of Science ®Google Scholar
• Gromann PM, Tracy DK, Giampietro V, Brammer MJ, Krabbendam L, Shergill SS. Examining frontotemporal connectivity and rTMS in healthy controls: implications for auditory hallucinations in schizophrenia. Neuropsychology 26(1), 127–132 (2012).
   PubMed Web of Science ®Google Scholar
• Giesel FL, Mehndiratta A, Hempel A et al. Improvement of auditory hallucinations and reduction of primary auditory area’s activation following TMS. Eur. J. Radiol. 81(6), 1273–1275 (2012).
   PubMed Web of Science ®Google Scholar
• Rosazza C, Minati L. Resting-state brain networks: literature review and clinical applications. Neurol. Sci. 32(5), 773–785 (2011).
   PubMed Web of Science ®Google Scholar
• Biswal BB, Mennes M, Zuo XN et al. Toward discovery science of human brain function. Proc. Natl Acad. Sci. USA 107(10), 4734–4739 (2010).
   PubMed Web of Science ®Google Scholar
• Behrens TE, Sporns O. Human connectomics. Curr. Opin. Neurobiol. 22(1), 144–153 (2012).
   PubMed Web of Science ®Google Scholar
• Mennes M, Zuo XN, Kelly C et al. Linking inter-individual differences in neural activation and behavior to intrinsic brain dynamics. Neuroimage 54(4), 2950–2959 (2011).
   PubMed Web of Science ®Google Scholar
• Kroken RA, Johnsen E. Is rational antipsychotic polytherapy feasible? A selective review. Curr. Psychiatr. Rep. 14(3), 244–251 (2012).
   PubMed Web of Science ®Google Scholar